|
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549 |
SCHEDULE 13D
Under the Securities Exchange Act of 1934
|
Calidi Biotherapeutics, Inc. (Name of Issuer) |
Common Stock (Title of Class of Securities) |
320703101 (CUSIP Number) |
Judd Kessler PO Box L, Rancho Santa Fe, CA, 92067 8583679545 (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications) |
05/01/2024 (Date of Event Which Requires Filing of This Statement) |
If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.
The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the
Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other
provisions of the Act (however, see the Notes).
SCHEDULE 13D
|
| CUSIP No. | 320703101 |
| 1 |
Name of reporting person
Kessler Judd S | ||||||||
| 2 | Check the appropriate box if a member of a Group (See Instructions)
(a)
(b)
| ||||||||
| 3 | SEC use only | ||||||||
| 4 |
Source of funds (See Instructions)
PF | ||||||||
| 5 |
Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)
| ||||||||
| 6 | Citizenship or place of organization
CALIFORNIA
| ||||||||
| Number of Shares Beneficially Owned by Each Reporting Person With: |
| ||||||||
| 11 | Aggregate amount beneficially owned by each reporting person
3,729,842.00 | ||||||||
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)
| ||||||||
| 13 | Percent of class represented by amount in Row (11)
5.0 % | ||||||||
| 14 | Type of Reporting Person (See Instructions)
IN |
SCHEDULE 13D
|
| Item 1. | Security and Issuer |
| (a) | Title of Class of Securities:
Common Stock |
| (b) | Name of Issuer:
Calidi Biotherapeutics, Inc. |
| (c) | Address of Issuer's Principal Executive Offices:
4475 EXECUTIVE DRIVE, SUITE 200, SAN DIEGO,
CALIFORNIA
, 92121. |
| Item 2. | Identity and Background |
| (a) | Judd Kessler |
| (b) | PO Box L
Rancho Santa Fe, CA 92067 |
| (c) | Investor |
| (d) | No |
| (e) | No |
| (f) | USA |
| Item 3. | Source and Amount of Funds or Other Consideration |
Personal savings | |
| Item 4. | Purpose of Transaction |
Invest in curing cancer | |
| Item 5. | Interest in Securities of the Issuer |
| (a) | I believe my 3,729,842 shares represent over 5% of the shares in CLDI |
| (b) | 3,729,842.00 |
| (c) | I've purchased 3546692
shares in the past 60 days |
| (d) | None |
| (e) | None |
| Item 6. | Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer |
None | |
| Item 7. | Material to be Filed as Exhibits. |
None |
| SIGNATURE | |
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
|
|
|